Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer (OUTREACH)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by Mina Alpha Limited
Information provided by (Responsible Party):
Mina Alpha Limited Identifier:
First received: March 11, 2016
Last updated: February 21, 2017
Last verified: February 2017

This is a First in Human study of a new single agent (MTL-CEBPA) in patients with advanced cancer of the liver. The study is in two parts. The first part is a dose escalation in patients with advanced hepatocellular carcinoma or patients presenting with secondary liver tumours. The second part is a dose expansion study in patients with hepatocellular carcinoma. All participants will be refractory to or ineligible for loco-regional therapy including surgery, radiofrequency tumour ablation or transarterial chemoembolisation and sorafenib.

MTL-CEBPA consists of a double stranded RNA formulated into a SMARTICLES® liposomal nanoparticle and is designed to activate the CEBPA gene.

Condition Intervention Phase
Hepatocellular Carcinoma
Liver Cancer
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A First-in-Human, Multi-centre, Open-label, Phase 1 Clinical Study With RNA Oligonucleotide Drug MTL-CEBPA to Investigate Its Safety and Tolerability in Patients With Advanced Liver Cancer

Resource links provided by NLM:

Further study details as provided by Mina Alpha Limited:

Primary Outcome Measures:
  • Incidence of Grade 3 or 4 drug related adverse events and clinical lab abnormalities defined as Dose Limiting Toxicities (DLTs) using NCI CTCAE v 4.03 [ Time Frame: During cycle 1 (28 days) of treatment ]

Secondary Outcome Measures:
  • Recommended Phase 2 Dose (RP2D) of MTL-CEBPA defined as the most appropriate dose to maximise a favourable risk/benefit reward for the participant population [ Time Frame: After completion of all Cycle 1 (28 days) of treatment for participant enrolled in part 1 ]
  • Total Active Pharmaceutical Ingredient (API) levels in plasma. [ Time Frame: The pharmacokinetics profile will be assessed by blood collection during Cycle 1 (28 days) of treatment ]
  • Preliminary evidence of liver function improvement [ Time Frame: Liver function will be assessed by blood collection twice weekly at every cycle (28 days) of treatment ]

Estimated Enrollment: 51
Actual Study Start Date: March 1, 2016
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MTL-CEBPA Drug: MTL-CEBPA

Intravenous administration into a vein (peripheral or central) on day 1, 8 and 15 of each 28-day cycle.

Number of Cycles: until progression or unacceptable toxicity develops.


Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed advanced advanced cancer characterised by hepatocellular carcinoma (HCC) or advanced stage cancer presenting with secondary liver tumours derived from extra hepatic primary cancer types.
  • At least one measurable lesion with target lesion size ≥ 1.0 cm as measured by MRI or CT
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Child-Pugh A or B7 disease (for HCC)
  • Willing to provide archived tumor tissue (if available) and willing to undergo pre- and on-treatment tumor biopsy (if considered safe and medically feasible by the treating investigator)

Exclusion Criteria:

  • Central nervous system metastases
  • Signs and symptoms of heart failure characterised as greater than New York Heart Association (NYHA) Class I
  • Patient presenting with a prolonged corrected QT (QTc) interval defined as ≥ 450ms (males) and ≥ 460ms (females) using Fridericia's correction formula; or other clinically significant cardiac abnormalities.
  • Platelets < 75 x 10^9/L
  • Absolute neutrophil count < 1.5 x 10^9/L
  • Serum albumin ≤ 28 g/L (for patients with cirrhosis only)
  • Alanine transaminase (ALT) and aspartate aminotransferase (AST) > 5 x Upper Limit of Normal (ULN)
  • Bilirubin > 50 μmol /L
  • Haemoglobin ≥ 9.0 g/dL
  • Prothrombin time (PT) ≥ 20 seconds
  • Serum creatinine > 1.5 x ULN
  • Estimated creatinine clearance < 60 mL/min/1.73 m2
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02716012

Contact: MiNA Alpha Limited

National Cancer Centre Not yet recruiting
Singapore, Singapore
Principal Investigator: Dr Han Chong Toh         
National University Hospital Not yet recruiting
Singapore, Singapore
Principal Investigator: Dr Cheng Ean Chee         
National Taiwan University Hospital Not yet recruiting
Taipei, Taiwan
Principal Investigator: Professor Kai-Wen Huang         
United Kingdom
University Hospitals Birmingham NHS Foundation Trust Recruiting
Birmingham, United Kingdom
Principal Investigator: Dr yuk-Ting Ma         
Cambridge University Hospitals NHS Trust Recruiting
Cambridge, United Kingdom
Principal Investigator: Dr Bristi Basu         
The Beatson West of Scotland Cancer Centre Recruiting
Glasgow, United Kingdom
Principal Investigator: Professor Jeff Evans         
Clatterbridge Cancer Centre NHS Foundation Trust Not yet recruiting
Liverpool, United Kingdom
Principal Investigator: Professor Daniel Palmer         
Guy's and St. Thomas' NHS Foundation Trust Recruiting
London, United Kingdom
Principal Investigator: Dr Debashis Sarker         
Imperial College Healthcare NHS Trust Recruiting
London, United Kingdom
Principal Investigator: Professor Long R Jiao         
University College London Hospitals NHS Foundation Trust Recruiting
London, United Kingdom
Principal Investigator: Professor Tim Meyer         
Newcastle upon Tyne Hospitals NHS Foundation Trust Recruiting
Newcastle, United Kingdom
Principal Investigator: Professor Ruth Plummer         
Sponsors and Collaborators
Mina Alpha Limited
Principal Investigator: Dr Debashis Sarker, MBChB, MRCP, PhD Guy's and St Thomas' NHS Foundation Trust and King's College London
Study Director: Professor Nagy Habib, MD, ChM, FRCS Mina Alpha Limited
  More Information

Additional Information:
Responsible Party: Mina Alpha Limited Identifier: NCT02716012     History of Changes
Other Study ID Numbers: MNA-3521-011
2015-003051-21 ( EudraCT Number )
20332 ( Other Identifier: UK NIHR CRN )
Study First Received: March 11, 2016
Last Updated: February 21, 2017
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Mina Alpha Limited:

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Liver Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases processed this record on May 24, 2017